Neuraminidase inhibitors in the treatment of adults with community acquired influenza: summary of trial data
| Treatment | Patients (% with proven influenza) | Age range (mean) | Duration of illness | Reduction in days to alleviation of symptoms in patients with influenza (median) | Comments | Investigator |
|---|---|---|---|---|---|---|
| Inhaled zanamivir 10 mg bid for 5 days | 417 (63%) | ⩾13 years (32 years) | ⩽48 h | 1 (5 v 4) | 3 days reduction in patients treated ⩽30 h | Hayden et al (1997)22 |
| 3 (7 v 4 in febrile) | ||||||
| Inhaled zanamivir 10 mg bid for 5 days | 455 (71%) | ⩾12 years (37 years) | <30 h and >30 h | 1.5 (6.5 v 5.0) | Reduced complications and antibiotics (15% v 38%) in patients with underlying conditions. No effect in patients with symptoms >30 h | MIST Study Group (1998)102 |
| 2.0 (6.5 v 4.5 in febrile) | ||||||
| Oseltamivir 75 mg or 150 mg bid for 5 days | 629 (60%) | 18–65 years | ⩽36 h | 1.4 (4.3 v 2.9 v 2.9) | Reduced complications | Treanor et al (2000)23 |
| Oseltamivir 75 mg or 150 mg bid for 5 days | 719 (66%) | 18–65 years | ⩽36 h | 1.2–1.5 days (4.9 v 3.6 v 3.4) | No difference between doses | Nicholson et al (2000)101 |